We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Effects of Pancreaticoduodenectomy on Glucose Metabolism

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01388192
Recruitment Status : Unknown
Verified January 2016 by National Taiwan University Hospital.
Recruitment status was:  Recruiting
First Posted : July 6, 2011
Last Update Posted : January 26, 2016
Information provided by (Responsible Party):
National Taiwan University Hospital

Brief Summary:
Pancreaticoduodenectomy (PD) involves removing the head of pancreas, duodenum, common bile duct, gall bladder, and/or distal stomach. In general, the postoperative changes are thought to be moderately severe, and about 20% of these patients go on to develop new clinical diabetes. PD-related factors of glucose metabolism will include removal of half of the pancreatic endocrine tissue, exclusion of the proximal small intestine, postoperative weight loss (on average, ~8% of body weight), and removal of putative diabetogenic factor in resected neoplasm. However, effect of removal of duodenum on glucose metabolism after PD has never been studied. The investigators plan to examine this issue by comparing fasting plasma levels of insulin, fasting plasma glucose, C-peptide, HbA1C, HOMA-insulin resistance, GLP-1 response after a standard meal, and body mass index (BMI) of patients before and after PD.

Condition or disease
Diabetes Mellitus Glucose Intolerance

Detailed Description:

Questionaire All studied patients will be requested to self-complete a detailed questionnaire that collects information on demographic data, including usual adult height and weight, and history of DM in first-degree relatives. Existing medical conditions, including DM, duration of these medical problems, and current medications will also be inquired. The database will also include details of weight measured at the time of recruitment and body mass index (BMI), calculated as weight (kg)/height2 (m2). All studied patients will have FBG levels measured. Patients receiving prescription antidiabetic medications for previously diagnosed DM will be classified as having DM regardless of their FBG value. Among patients not reporting treatment for DM, classification of DM status will be based on the American Diabetes Association criteria; patients will be classified as having DM if the FBG level is ≧126 mg/dL (7 mmol/L), as having impaired fasting glucose (IFG) if their FBG is between 100 and 125 mg/dL (5.6-6.9 mmol/L), and as having normal fasting glucose (NFG) if their FBG value is ≦99 mg/dL (5.5 mmol/L).

After withdrawal of anti-diabetic medications for 12 h, the patients were asked to fast overnight for 12 h, then were given 200 ml of formula (220kcal, 14g of protein, 28 g of carbohydrates, and 5 g of fat; Modifast, Stocksund, Sweden) within 10 min through a NG tube on post-operative day 5 (proximal feeding group [PFG]) and a jejunostomy feeding tube (distal feeding group [DFG]) on post-operative day 6. The below parameter will be checked, including

  1. HOMA insulin resistance assessment (HOMA-IR)
  2. GLP-1
  3. GIP
  4. C-peptide
  5. Insulin
  6. Glucose

Layout table for study information
Study Type : Observational
Estimated Enrollment : 100 participants
Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Effects of Pancreaticoduodenectomy on Glucose Metabolism
Study Start Date : November 2011
Estimated Primary Completion Date : December 2016
Estimated Study Completion Date : December 2016

Receiving pancreaticoduodenectomy

Primary Outcome Measures :
  1. Change of glucose metabolism after pancreaticoduodenectomy [ Time Frame: on the post-operative day 5 and day 6 ]
    Measurement of glucose, glucagon-like peptide-1, Measurement of insulin, C-peptide, and glucagon concentrations after meal test

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients receiving pancreaticoduodenectomy

Inclusion Criteria:

  • Patients receiving pancreaticoduodenectomy

Exclusion Criteria:

  • history of pancreatitis
  • hepatic dysfunction (Child-Pugh > 2)
  • renal dysfunction (serum creatinine concentration > 3 mg/L, hemodialysis, or both)
  • pregnancy

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01388192

Layout table for location contacts
Contact: Yu-Wen Tien, M.D., Ph.D. +886-0972651427 Ywtien5106@ntu.edu.tw

Layout table for location information
National Taiwan University Hospital Recruiting
Taipei, Taiwan, 100
Contact: Yu-Wen Tien, Ph.D.    +886-972651427    kptkptkpt@yahoo.com.tw   
Principal Investigator: Yu-Wen Tien, Ph.D.         
Sponsors and Collaborators
National Taiwan University Hospital
Layout table for investigator information
Study Chair: Yu-Wen Tien, M.D., Ph.D. National Taiwan University Hospital
Layout table for additonal information
Responsible Party: National Taiwan University Hospital
ClinicalTrials.gov Identifier: NCT01388192    
Other Study ID Numbers: 201104028RC
First Posted: July 6, 2011    Key Record Dates
Last Update Posted: January 26, 2016
Last Verified: January 2016
Keywords provided by National Taiwan University Hospital:
sugar metabolism
Additional relevant MeSH terms:
Layout table for MeSH terms
Glucose Intolerance
Glucose Metabolism Disorders
Metabolic Diseases